Ultime notizie per Central Automotive (OTC:CEAVF) Azioni

Central Automotive Products Ltd is engaged in the business of developing automobile parts. The product line includes - Timing parts, piston rings, cylinder liners, engine bearing, transmission parts, suspension parts, steering parts, shock absorber, brake parts, clutch, cooling parts, air conditioning parts, filter, cable, and engine oil.

CENTRAL AUTOMOTIVE PRODS by Central Automotive Products Ltd.

Central Automotive Products Ltd

Wolfe Research analyst Tim Anderson initiates coverage on Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Peer Perform rating.

News

Initiation

Analyst Ratings

AMGN

Wolfe Research Initiates Coverage On Amgen with Peer Perform Rating

Wolfe Research analyst Akash Tewari initiates coverage on Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Outperform rating and announces Price Target of $95.

Price Target

BMRN

Wolfe Research Initiates Coverage On Biomarin Pharmaceutical with Outperform Rating, Announces Price Target of $95

Wolfe Research analyst Alexandria Hammond initiates coverage on Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Peer Perform rating.

BIIB

Wolfe Research Initiates Coverage On Biogen with Peer Perform Rating

Wolfe Research analyst Alexandria Hammond initiates coverage on AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Outperform rating and announces Price Target of $205.

ABBV

Wolfe Research Initiates Coverage On AbbVie with Outperform Rating, Announces Price Target of $205

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Buy and maintains $135 price target.

Reiteration

BPMC

Needham Reiterates Buy on Blueprint Medicines, Maintains $135 Price Target

Needham analyst Gil Blum reiterates Celcuity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) with a Buy and maintains $23 price target.

CELC

Needham Reiterates Buy on Celcuity, Maintains $23 Price Target

Needham analyst Ryan Koontz reiterates Gilat Satellite Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILT#NASDAQ">GILT</a>) with a Buy and maintains $8.5 price target.

GILT

Needham Reiterates Buy on Gilat Satellite Networks, Maintains $8.5 Price Target

<ul>
<li>Aegon today announces a planned new EUR 150 million share buyback program, consistent with its policy to return excess Cash Capital at Holding to shareholders in the absence of value-creating opportunities. Barring unforeseen circumstances, the share buyback program will start at the beginning of January 2025 and is expected to be completed on or before June 30, 2025. The start of this share buyback program will be announced separately in due course.&nbsp;</li>
<li>The new planned EUR 150 million share buyback program will include an amount of about EUR 40 million to meet Aegon's obligations resulting from the share-based compensation plans for senior management. The repurchased shares resulting from these compensation plans will be held as treasury shares until they are allocated to the plan participants. Aegon intends to cancel the remainder of the repurchased shares resulting from the new planned share buyback program, subject to any relevant approval.</li>
</ul>

Aegon Announces €150M Share Buyback Starting January 2025, With €40M For Compensation And The Rest For Cancellation, Pending Approval

Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has filed a lawsuit against the Health Resources and Services Administration (HRSA). The pharmaceutical giant claims that HRSA obstructed its attempt to alter drug discount offerings to hospitals.
What Happened: As per Eli Lilly&#8217;s official statement on Thursday, the conflict centers on the federal 340B program, which requires drug manufacturers to offer discounts to healthcare providers serving low-income communities. Participation in this program is crucial for drug companies to secure funding from government health insurance programs like Medicare and Medicaid.
Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on a weekly basis. However, HRSA, a division of the U.S. Health and Human Services Department, rejected this approach, stating it was inconsistent with the 340B law.
&#8220;HRSA does not have the authority to arbitrarily reject this model, which serves the original goals of the 340B program and improves transparency, efficiency, and program integrity,&#8221; the statement read.
See Also: <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a>
Why It Matters: The lawsuit comes amid ongoing scrutiny of drug pricing practices. Recently, <a href="https://www.benzinga.com/general/biotech/24/11/41940958/humanitarian-organization-criticizes-eli-lilly-novo-nordisk-and-sanofi-of-having-double-standards-for-high-insulin-price">Doctors Without Borders</a> criticized Eli Lilly and other insulin manufacturers for maintaining high prices, urging them to provide affordable insulin to low- and middle-income countries.
This legal action also <a href="https://www.benzinga.com/general/biotech/24/11/41941391/johnson-johnson-challenges-government-drug-pricing-dispute-over-two-drugs">follows a similar lawsuit</a> by Johnson &amp; Johnson, which alleged the Health and Human Services Department of blocking its drug rebate plans. The 340B program has been subject to extensive legal challenges, with a U.S. appeals court previously allowing drugmakers to limit the use of outside pharmacies for dispensing under the program.
Meanwhile, Eli Lilly has been in the spotlight for its <a href="https://www.benzinga.com/24/11/41985752/eli-lillys-detailed-phase-3-trial-data-show-99-of-patients-on-popular-mounjarozepbound-remained-diabetes-free-for-even-at-three-years">Phase 3 trial data</a> of tirzepatide, marketed as Mounjaro and Zepbound. The study showed promising results in reducing the risk of type 2 diabetes in patients with pre-diabetes and obesity, highlighting the company&#8217;s focus on innovative treatments.
Price Action: Eli Lilly was down by 0.28% during pre-market hours on Friday at the time of writing, as per <a href="https://pro.benzinga.com">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/41921267/new-jersey-is-making-history-by-offering-medical-cannabis-as-employee-benefit?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">New Jersey Is Making History By Offering Medical Cannabis</a></li>
</ul>
Image via Shutterstock
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Biotech

Government

Health Care

General

Mounjaro-Maker Eli Lilly Files Lawsuit Against US Agency Over Drug Rebate Program

Needham analyst James Ricchiuti reiterates 3D Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) with a Hold.

Needham Reiterates Hold on 3D Sys

Aegon trading update for third quarter 2024&nbsp;
• EUR 336 million operating capital generation, before holding funding and operating expenses. Full-year 2024 guidance raised to around EUR 1.2 billion, from around EUR 1.1 billion previously&nbsp;
• Capital ratios of the main units remain above their respective operating levels&nbsp;
• Planned new EUR 150 million share buyback program announced; completion expected in the first half of 2025. The program includes neutralization of shares issued for share-based compensation plans&nbsp;
• Cash Capital at Holding of EUR 1.5 billion as of September 30, 2024. Expect to reach mid-point of the target range (EUR 1.0 billion) by the end of 2026&nbsp;
• Completed program to purchase institutionally owned universal life policies. Terminated policies negatively impacted US RBC ratio by 16%-points. Expect 8%-points benefit in 4Q 2024 after equity funding repayment. Operating capital generation benefits from the program, as previously guided&nbsp;
• Strong commercial momentum in Asset Management and UK Workplace platform. US Strategic Assets experience c

Aegon Q3 Business Update: Operating Capital Generation €336M Before Holding Expenses; Raised FY24 Operating Capital Target To ~€1.2B, Up From The Previous Estimate Of €1.1B

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy and maintains $8 price target.

GOVX

HC Wainwright & Co. Reiterates Buy on Geovax Labs, Maintains $8 Price Target

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) with a Buy and maintains $9 price target.

INKT

HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $9 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) with a Neutral.

STTK

HC Wainwright & Co. Reiterates Neutral on Shattuck Labs

Macro Economic Events

Econ #s

Economics

U.K. Labour Productivity For Q2 0.2% Vs. 0.1% Prior

HC Wainwright &amp; Co. analyst Yi Chen reiterates Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) with a Buy and maintains $14 price target.

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

HC Wainwright & Co. Reiterates Buy on Orchestra BioMed Hldgs, Maintains $14 Price Target

Coca-Cola European Partners plc Ordinary Shares

CCEP

Coca-cola Europacific Partners Says The Financial Conduct Authority Approved Its Transfer Of Listing Category From Equity Shares Category To Equity Shares (Commercial Companies) Category Of Official List

Michael Burry, the hedge fund manager renowned for predicting the 2008 financial crisis, has significantly increased his exposure to Chinese technology companies while simultaneously implementing protective measures against potential downside risks, <a href="https://www.benzinga.com/markets/asia/24/11/42000692/david-teppers-appaloosa-trims-alibaba-stake-by-476-in-q3-2024-doubles-down-on-pdd-holdings-and-jd.com">according to regulatory filings</a>.
What Happened: Burry&#8217;s Scion Asset Management made several notable adjustments to its portfolio during the third quarter, with Chinese companies now representing its largest positions. The firm increased its stake in Alibaba Group Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) by 29%, making it the fund&#8217;s largest holding valued at over $21 million as of September&#8217;s end.
In a similar move, Scion doubled its position in JD.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), elevating it to the fund&#8217;s second-largest holding at approximately $20 million. The firm also expanded its stake in Chinese search giant Baidu Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) by 67%, bringing the position to $13.2 million.
However, in what appears to be a cautionary strategy, Burry has simultaneously established put options against these same holdings. Put options typically increase in value when the underlying securities decline, suggesting a hedging strategy designed to protect against potential market volatility.
See Also: <a href="https://www.benzinga.com/news/global/24/11/41999238/ross-gerber-blasts-teslas-support-for-ending-ev-tax-credit-as-insanity-amid-reported-policy-shift-under-trump-administration">Long-Time Tesla Bull Rages As Elon Musk Reportedly Backs Trump&#8217;s Plan To Ax $7.5K EV Credit: &#8216;Insanity&#8217;</a>
The timing of these moves coincides with Beijing&#8217;s recent economic stimulus announcements aimed at reinvigorating growth in the world&#8217;s second-largest economy. While Chinese equities initially rallied in September following these signals, gains have moderated as investors await more concrete fiscal measures.
Beyond his Chinese technology focus, Burry has also increased positions in several U.S. companies, including Shift4 Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>), American Coastal Insurance Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>), and Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>).
Why It Matters: Burry&#8217;s <a href="https://www.benzinga.com/markets/equities/24/10/41248334/big-short-investor-michael-burrys-china-bet-pays-off-as-top-picks-surge-nearly-60-in-2-months">top three Chinese holdings</a> have posted average gains of nearly 60% over a two-month period, according to market data.
Burry&#8217;s moves are being closely watched by market participants, particularly given his track record. He gained widespread recognition for his prescient bet against mortgage-backed securities before the 2008 global financial crisis, a story later chronicled in Michael Lewis&#8216;s bestseller &#8220;The Big Short&#8221; and its subsequent Oscar-winning film adaptation.
It&#8217;s worth noting that these positions reflect holdings as of Sep. 30, as required by SEC regulations for funds managing over $100 million in assets. Given the 45-day reporting delay and Burry&#8217;s active trading style, current positions may have already changed.
The development comes as other <a href="https://www.benzinga.com/markets/asia/24/11/42000692/david-teppers-appaloosa-trims-alibaba-stake-by-476-in-q3-2024-doubles-down-on-pdd-holdings-and-jd.com">prominent investors adjust their Chinese holdings</a>. Billionaire investor David Tepper&#8217;s Appaloosa Management recently reduced its Alibaba stake by 5%, though the position remains the fund&#8217;s largest holding at 15.75% of its $6.7 billion portfolio.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/content/41999311/jim-cramer-says-these-10-frothy-stocks-are-up-over-200-ytd-including-rocket-lab-palantir-and-carvana">Jim Cramer Says These 10 &#8216;Frothy&#8217; Stocks Are Up Over 200% YTD, Including Rocket Lab, Palantir, And Carvana</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Comments

Central Automotive

Notizie

Ultime notizie per Central Automotive (OTC:CEAVF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO